Stockscreener 앱 받기
1.60
1.27%
0.02
시간 외 거래:
1.56
-0.04
-2.50%
전일 마감가:
$1.58
열려 있는:
$1.58
하루 거래량:
1.71M
Relative Volume:
0.58
시가총액:
$243.35M
수익:
$137.74M
순이익/손실:
$-27.97M
주가수익비율:
-1.3675
EPS:
-1.17
순현금흐름:
$-9.61M
1주 성능:
+4.58%
1개월 성능:
+45.45%
6개월 성능:
-51.95%
1년 성능:
-9.60%
1일 변동 폭
$1.50
$1.60
1주일 범위
$1.46
$1.62
52주 변동 폭
$1.04
$3.93
Heron Therapeutics Inc Stock (HRTX) Company Profile
명칭
Heron Therapeutics Inc
전화
(858) 251-4400
주소
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
HRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.60 | 243.35M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2024-04-23 | 개시 | CapitalOne | Overweight |
| 2024-03-13 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Buy |
| 2020-02-20 | 재확인 | Needham | Buy |
| 2019-01-16 | 재확인 | Needham | Buy |
| 2018-04-05 | 개시 | Evercore ISI | Outperform |
| 2018-03-19 | 재확인 | Mizuho | Buy |
| 2018-03-01 | 재확인 | Needham | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Outperform |
| 2017-09-27 | 개시 | Northland Capital | Outperform |
| 2017-02-27 | 개시 | Needham | Buy |
| 2016-10-26 | 개시 | Aegis Capital | Buy |
| 2016-09-06 | 재개 | Lake Street | Buy |
| 2016-05-03 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-10 | 개시 | Lake Street | Buy |
| 2015-09-23 | 재확인 | Leerink Partners | Outperform |
| 2015-09-02 | 개시 | BofA/Merrill | Buy |
| 2015-08-03 | 재확인 | Brean Capital | Buy |
| 2015-06-30 | 재확인 | JMP Securities | Mkt Outperform |
| 2015-06-19 | 재확인 | Leerink Partners | Outperform |
| 2014-08-07 | 개시 | Noble Financial | Buy |
모두보기
Heron Therapeutics Inc 주식(HRTX)의 최신 뉴스
California public company relocates to North Carolina - The Business Journals
Heron Therapeutics Relocates Headquarters to North Carolina - TipRanks
Heron Therapeutics, Inc. Announces Corporate Headquarters Relocation to Cary, North Carolina - Marketscreener.com
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to “Hold” at StockNews.com - Defense World
Heron Therapeutics (NASDAQ:HRTX) Cut to "Hold" at StockNews.com - MarketBeat
Fmr LLC Has $859,000 Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Verition Fund Management LLC - Defense World
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stake Lowered by Charles Schwab Investment Management Inc. - Defense World
U.S. District Court Upholds Validity of CINVANTI® Patents - The Eastern Progress Online
Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer - The Eastern Progress Online
StockNews.com Upgrades Heron Therapeutics (NASDAQ:HRTX) to "Buy" - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Increased to Buy at StockNews.com - Defense World
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance - Kilgore News Herald
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors - The Eastern Progress Online
StockNews.com Downgrades Heron Therapeutics (NASDAQ:HRTX) to Hold - Defense World
Relief For Heron Therapeutics After The Court Win On Cinvanti - Seeking Alpha
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Heron Therapeutics wins patent case for CINVANTI drug - Investing.com
Heron Therapeutics wins patent case for CINVANTI drug By Investing.com - Investing.com Canada
Heron Therapeutics Shares Soar 91% on Patent Dispute Win - MarketWatch
Heron Therapeutics Wins Major Patent Battle Over CINVANTI, Blocks Generic Until 2035 - StockTitan
Heron Therapeutics: Approved Therapy With Blockbuster Potential But Meager Revenues (NASDAQ:HRTX) - Seeking Alpha
Biotech Finds Mid-Week Success Following Q4 Earnings Release - MSN
Principal Financial Group Inc. Has $204,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Heron Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to “Hold” - Defense World
Heron Therapeutics (NASDAQ:HRTX) Downgraded by StockNews.com to "Hold" - MarketBeat
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Heron Therapeutics Q3 2024 Earnings Preview - MSN
Heron Therapeutics Inc (NASDAQ: HRTX) Declines -1.68%: This $177.95 million Stock Could Go Down -669.23% - Stocks Register
Short Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Declines By 6.0% - MarketBeat
Northland Capmk Has Pessimistic View of HRTX Q4 Earnings - Defense World
Equities Analysts Set Expectations for HRTX Q4 Earnings - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Raised to Buy at StockNews.com - Defense World
Heron Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Needham & Company LLC Has Lowered Expectations for Heron Therapeutics (NASDAQ:HRTX) Stock Price - MarketBeat
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge - Simply Wall St
Heron Therapeutics Inc (HRTX) Quarterly 10-Q Report - Quartz
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30% - Simply Wall St
Earnings call: Heron Therapeutics projects higher Q4 revenue By Investing.com - Investing.com UK
Starbucks To $77? Here Are 10 Top Analyst Forecasts For WednesdayStarbucks (NASDAQ:SBUX) - Benzinga
Heron Therapeutics Reports Q3 2024 Results and Narrows Guidance - TipRanks
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Heron Therapeutics reports Q3 EPS (3c), consensus (3c) - TipRanks
Heron Therapeutics (HRTX) Set to Announce Earnings on Tuesday - Defense World
Heron Therapeutics Inc (HRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
1.47%
자본화:
|
볼륨(24시간):